Preclinical Data Presented at AACR 2018 Shows Esperance Pharmaceuticals' EP-100 Is Synergistic with PARP Inhibitor Olaparib in Ovarian Cancer
Studies Conducted by MD Anderson Cancer Center Elucidate the Mechanisms by Which EP-100 Kills Ovarian Cancer Cells on Its Own and Synergistically in Combination with a Leading PARP Inhibitor
Page (1) of 1 - 04/16/18||
(April 16, 2018)
This article is no longer available,but here are some related topics.
HTN - Health Technology Net
DMN Newswire Newsletter
All Rights Reserved